Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients ...

There seems to be a strong exposure-response relationship between nerandomilast and the preservation of FVC in patients with PPF and IPF.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...

Single drugs targeting single biological pathways are insufficient for complex diseases,” Remedy Cell Ltd. CEO Ayelet Dilion Mashiah told BioWorld. Remedy is taking a secretome-based approach to treat ...

Trevi Therapeutics shifts to late-stage biotech with Haduvio for IPF chronic cough. Click here to read my latest analysis of ...

Deupirfenidone slowed the progression of lung disease over 26 weeks in patients with idiopathic pulmonary fibrosis in a clinical trial.

An interdisciplinary research team led by Dr. Elisha Krieg at the Leibniz Institute of Polymer Research Dresden (IPF) has successfully synthesized and characterized Olympic gels, a long-theorized ...

Icon Solutions -- the UK fintech enabling banks globally to design and implement state-of-the-art payment systems -- has appointed Anders Olofsson as Sales Director, EMEA to drive adoption of the Icon ...

An interdisciplinary research team led by Dr. Elisha Krieg at the Leibniz Institute of Polymer Research Dresden (IPF) has ...

The acquisition brings together the gold standard for continuous ambulatory cough monitoring and lung sound analysis ...

Following Easter weekend’s river overflow, East Lansing residents are preparing for the Red Cedar River to soon flood again.

Idiopathic pulmonary fibrosis (IPF) is a fatal disease that's all the more difficult for patients because of a lack of awareness and investment in supporting people with the condition. In the week of ...